8 completed, 4 unknown, 3 active not recruiting, 2 recruiting. 7 Phase 2, 4 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Unknown 2 |
| Phase 1 | 4 | Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Macrophage Activation Syndrome: new trials by email Literature Review of Macrophage Activation Syndrome trials Research Report on Macrophage Activation Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS) Kawasaki Disease, Macrophage Activation Syndrome (MAS) | Not yet recruiting | Meyer Children's Hospital IRCCS | 150 | 2026-02-01 | 2026-03-25 | |
| Assessment of Macrophage Activation syndromE in STill's Disease in Italy Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset | Completed | Swedish Orphan Biovitrum | 32 | 2025-06-06 | 2025-12-02 | |
| Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace Human Anaplasmosis | Recruiting | University Hospital, Strasbourg, France | 100 | 2024-10-02 | 2025-12-31 | |
| Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2024-07-02 | 2026-09-10 | |
| Assessment of Macrophage Activation syndromE in STill's Disease Chart review - Macrophage Activation Syndrome, Still's Disease, Adult-Onset | Completed | Swedish Orphan Biovitrum | 75 | 2023-09-27 | 2026-10-05 | |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) Placebo, Anakinra - Dengue, Dengue With Warning Signs | Phase 2 | Active not recruiting | Oxford University Clinical Research Unit, Vietnam | 160 | 2023-01-02 | 2026-01-06 |
| Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome Ruxolitinib, methylprednisolone - Macrophage Activation Syndrome | Phase 3 | Unknown | Beijing Friendship Hospital | 40 | 2022-06-01 | 2022-03-17 |
| Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Emapalumab - Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis | Phase 3 | Completed | Swedish Orphan Biovitrum | 33 | 2021-12-15 | 2026-08-26 |
| Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Anakinra, Tocilizumab - COVID-19, Virus Diseases | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 102 | 2020-04-02 | 2021-01-11 |
| Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis Blood samples - Macrophage Activation Syndrome | Not applicable | Completed | University Hospital, Rouen | 27 | 2019-03-21 | 2026-01-22 |
| Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis | Active not recruiting | National Cancer Institute (NCI) | 500 | 2019-01-23 | 2026-10-08 | |
| A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Emapalumab - Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic | Phase 2 | Completed | Swedish Orphan Biovitrum | 14 | 2018-02-20 | 2022-05-17 |
| A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis Anakinra, Recombinant human interferon-gamma, Placebo - Sepsis, Macrophage Activation Syndrome | Phase 2 | Completed | Hellenic Institute for the Study of Sepsis | 36 | 2017-12-15 | 2020-07-29 |
| Treatment of Macrophage Activation Syndrome (MAS) With Anakinra kineret, placebo - Macrophage Activation Syndrome | Phase 1 | Terminated | University of Alabama at Birmingham | 9 | 2016-05-15 | 2024-08-01 |
| Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） Interleukin-2 - Macrophage Activation Syndrome | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 6 | 2014-06-01 | 2015-10-06 |
| CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide - Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | Unknown | Diane George | 14 | 2013-06-03 | 2024-06-04 |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation CD34 Stem Cell Selection Therapy - Bone Marrow Failure Syndrome, Severe Aplastic Anemia | Phase 1 / Phase 2 | Active not recruiting | Diane George | 37 | 2013-03-01 | 2025-08-14 |
| New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic | Unknown | Amrita Institute of Medical Sciences & Research Center | 50 | 2010-03-01 | 2010-03-30 | |
| Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS) | Completed | Gunnar Lachmann | 2623 | 2000-01-01 | 2022-12-07 |
Lymphohistiocytosis, Hemophagocytic (7) · Arthritis, Juvenile (6) · Still's Disease, Adult-Onset (3) · Acquired Immunodeficiency Syndrome (2) · Anemia, Aplastic (2) · Anemia, Diamond-Blackfan (2) · Anemia, Sickle Cell (2) · Bone Marrow Failure Disorders (2) · Cytokine Release Syndrome (2) · Hemoglobinopathies (2) · Histiocytosis (2) · Histiocytosis, Langerhans-Cell (2) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (2) · Primary Immunodeficiency Diseases (2)
Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphoproliferative Disorders (19) · Hemic and Lymphatic Diseases (9) · Lymphatic Diseases (8) · Histiocytosis, Non-Langerhans-Cell (7) · Skin and Connective Tissue Diseases (7) · Arthritis (6) · Autoimmune Diseases (6) · Connective Tissue Diseases (6) · Infections (6) · Joint Diseases (6) · Musculoskeletal Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6)
Interleukin 1 Receptor Antagonist Protein (4) · Emapalumab (2) · Methylprednisolone (2) · Saline Solution (2) · Alemtuzumab (1) · Blood Specimen Collection (1) · Busulfan (1) · Cyclophosphamide (1) · Interleukin-2 (1) · Melphalan (1) · Methylprednisolone Hemisuccinate (1) · Tacrolimus (1) · Thiotepa (1) · World Health Organization (1) · aldesleukin (1)
Swedish Orphan Biovitrum (4) · Diane George (2) · Hellenic Institute for the Study of Sepsis (2) · Amrita Institute of Medical Sciences & Research Center (1) · Beijing Friendship Hospital (1) · Gunnar Lachmann (1) · Meyer Children's Hospital IRCCS (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oxford University Clinical Research Unit, Vietnam (1) · Peking University People's Hospital (1) · University Hospital, Rouen (1) · University Hospital, Strasbourg, France (1) · University of Alabama at Birmingham (1)
United States (8) · France (5) · Italy (5) · Spain (3) · Canada (2) · China (2) · Germany (2) · Greece (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · India (1) · Japan (1) · Poland (1)
Diane George, MD (2) · Antonios Papadopoulos, MD, PhD (1) · Apostolos Armaganidis, MD, PhD (1) · Gunnar Lachmann, MD (1) · Joseph M Rocco, M.D. (1) · Randall Q Cron, MD (1) · Sharath Kumar, MD (1) · Sophie Yacoub (1) · Srivandana Akshintala, M.D. (1) · Uwe Ullman, MD (1) · Walter W Chatham, MD (1) · Zhanguo Li (1)
PMID 14987884, PMID 16003060, PMID 20597663, PMID 22822024, PMID 24183799, PMID 26584195, PMID 26903338, PMID 27418577, PMID 27856268, PMID 28918754, PMID 30010630, PMID 30766533, PMID 31513353, PMID 31626037, PMID 32209661, PMID 32448380, PMID 34252125, PMID 36384100, PMID 37001971, PMID 37394115, PMID 37486616, PMID 38662147, PMID 39418210, PMID 39931105, PMID 40953923, PMID 9176497, PMID 9233735
2017 (1)